2. In the phase I portion of the study all patients with relapsed or refractory AML are eligible. For the Phase II portion of the study, patients must have AML progressing from prior MPN (MPN-BP) or have MDS/MPN with more than 20% blasts. Temporary prior measures to control blood counts, such as apheresis or hydrea are allowed. Patients with newly diagnosed or previously treated disease are eligible as long as prior therapy does not include hypomethylating agents. Prior therapy for RUXOLITINIB for MPN is allowed.